Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer
ConditionSmall Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAHS Cancer Control Alberta
About this trial
The purpose of this study is to find out what effects of using adaptive radiotherapy to deliver chest radiation has on the ability to control lung cancer and side effects.
Eligibility criteria
Qualifiers
Minimum 18 years of age
Biopsy proven, newly diagnosed, untreated SCLC
Completed standard of care staging investigations including: CT chest/abdomen/pelvis, bone scan and/or or PET-CT scan, CT head or MRI brain, or chest X-ray
Eligible for platinum doublet chemotherapy
Disqualifiers
No intrathoracic disease seen to target with radiation
Thoracic disease is contiguous to extra-thoracic sites, beyond ipsilateral supraclavicular lymph nodes
Mixed histology disease
Active serious infection requiring therapy
Trial design
Treatments tested in this trial
- Dose-escalated adaptive radiotherapy
- Chemotherapy
Treatment groups
31 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov